Trial reportJAMA network open2026
Concentrated Exposure Therapy vs Internet-Based Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Trial report in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Given the high prevalence, chronicity, and associated disability of obsessive-compulsive disorder (OCD), optimizing treatment is a global priority. The Bergen 4-day treatment (B4DT), a concentrated exposure-based intervention, may reduce treatment burden and improve access to evidence-based care. Objective: To evaluate the efficacy of B4DT compared with internet-based cognitive behavioral therapy (iCBT) in reducing OCD symptom severity. Design, Setting, and Participants: Single-center randomized controlled trial (1:1 allocation). Between May 8, 2024, and August 8, 2025, adults (aged 18 to 72 years) with OCD were enrolled and were followed up for 3 months. Key exclusion criteria included schizophrenia, bipolar disorder, acute suicidality, substance dependence, and recent psychopharmacological changes. Outcomes were assessed at baseline, 6 weeks, 8 weeks (posttreatment), and 3 months (follow-up) by masked evaluators. Interventions: Patients were randomized to B4DT (including preparatory sessions) or an 8-week unguided iCBT program. Main Outcomes and Measures: The primary outcome was the change in OCD symptom severity, measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Secondary outcomes included self-reported OCD (OCI-R), dysfunctional cognitions, quality of life, depressive symptoms, experiential avoidance, global functioning, self-esteem, and treatment satisfaction. Results: A total of 253 individuals were screened, and 119 were enrolled after 53 were found to be ineligible and 81 declined to participate. Sixty of the 119 randomized participants (mean [SD] age, 33.5 [10.1] years; 79 [66.4%] women) were assigned to B4DT and 59 to iCBT. The primary analysis included all randomized participants (intention-to-treat). B4DT was associated with significantly greater reductions in OCD symptoms (Y-BOCS) than iCBT, with large effects at posttreatment (mean [SE] difference, -7.9 [0.9]; 95% CI, -9.7 to -6.0; Hedges g, -1.6) and sustained effects at 3-month follow-up (mean [SE] difference, -5.6 [1.1]; 95% CI, -7.8 to -3.4; Hedges g, -1.0). Secondary outcomes consistently favored B4DT. Response and remission rates at 3-month follow-up were higher with B4DT (35 of 57 [61.4%] vs 11 of 44 [25.0%] and 24 of 57 [42.1%] vs 6 of 44 [13.6%], respectively). Conclusions and Relevance: In this randomized clinical trial of 119 adults with OCD, B4DT was superior to iCBT in reducing OCD symptom severity, with sustained benefits. Its brief, concentrated format may represent a scalable strategy to improve access to effective OCD treatment globally. Trial Registration: German Clinical Trials Register: DRKS00034236.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.